Form 4: Corcept Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 25,000 shares of common stock on September 1, 2026.
Summary
- Option exercise/conversion: acquired 25,000 Common Stock at $8.27 ($206,750) on September 1, 2026; holds 34,755 after (Direct).
- Open-market sale: disposed of 11,730 Common Stock at $113.94 ($1,336,459) on September 1, 2026; holds 23,025 after (Direct).
- Open-market sale: disposed of 10,989 Common Stock at $114.71 ($1,260,568) on September 1, 2026; holds 12,036 after (Direct).
- Open-market sale: disposed of 2,281 Common Stock at $115.61 ($263,711) on September 1, 2026; holds 9,755 after (Direct).
- Grant/award: acquired 150 Common Stock at $113.38 ($17,007) on September 1, 2026; holds 9,905 after (Direct).
- Grant/award: acquired 150 Common Stock on September 1, 2026; holds 10,055 after (Direct).
- Tax/exercise-price withholding: disposed of 117 Common Stock at $113.38 ($13,265) on September 2, 2026; holds 9,938 after (Direct).
- Option exercise/conversion: disposed of 25,000 Stock option (right to buy) on September 1, 2026; holds 66,986 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,860,737 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Sean Maduck — Officer (See Remarks)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Option exercise/conversion | Common Stock | 25,000 | $8 | $206.8K | 34,755 |
| 2026-09-01 | Open-market sale | Common Stock | 11,730 | $114 | $1.3M | 23,025 |
| 2026-09-01 | Open-market sale | Common Stock | 10,989 | $115 | $1.3M | 12,036 |
| 2026-09-01 | Open-market sale | Common Stock | 2,281 | $116 | $263.7K | 9,755 |
| 2026-09-01 | Grant/award | Common Stock | 150 | $113 | $17.0K | 9,905 |
| 2026-09-01 | Grant/award | Common Stock | 150 | — | — | 10,055 |
| 2026-09-02 | Tax/exercise-price withholding | Common Stock | 117 | $113 | $13.3K | 9,938 |
| 2026-09-01 | Option exercise/conversion | Stock option (right to buy) | 25,000 | — | — | 66,986 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Option exercise/conversion (25,000 shares) |
| 2026-09-01 | Open-market sale (11,730 shares) |
| 2026-09-01 | Open-market sale (10,989 shares) |
| 2026-09-01 | Open-market sale (2,281 shares) |
| 2026-09-01 | Grant/award (150 shares) |
| 2026-09-01 | Grant/award (150 shares) |
| 2026-09-02 | Tax/exercise-price withholding (117 shares) |
| 2026-09-01 | Option exercise/conversion (25,000 shares) |
Keywords
insider transaction, Form 4, CORT, CORCEPT THERAPEUTICS INC, bearish, Sean Maduck
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.